Retrospective cohort study assesses corticosteroid therapy outcomes in distinct clinical phenotypes, suggesting tailored treatment strategies.
Key Points
Corticosteroid therapy was linked to improved outcomes in community-acquired pneumonia patients, especially those in phenotype C.
Patients with phenotype C showed a significant survival benefit from intravenous corticosteroids with an optimal dose of 80 mg/d.
Analysis included logistic regression and Cox proportional hazards models to examine the efficacy of corticosteroid treatment across different phenotypes.
Findings suggest that phenotype-guided therapy may optimize treatment strategies and enhance patient outcomes in community-acquired pneumonia.